Key Laboratory of Integrated Oncology and Intelligent Medicine of Zhejiang Province, Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
National Health Commission (NHC) Key Laboratory of Combined Multi-organ Transplantation, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Immunol. 2022 May 11;13:879552. doi: 10.3389/fimmu.2022.879552. eCollection 2022.
Inflammation is crucial to tumorigenesis and the development of metastasis. Hepatic ischemia/reperfusion injury (IRI) is an unresolved problem in liver resection and transplantation which often establishes and remodels the inflammatory microenvironment in liver. More and more experimental and clinical evidence unmasks the role of hepatic IRI and associated inflammation in promoting the recurrence of hepatocellular carcinoma (HCC). Meanwhile, approaches aimed at alleviating hepatic IRI, such as machine perfusion, regulating the gut-liver axis, and targeting key inflammatory components, have been proved to prevent HCC recurrence. This review article highlights the underlying mechanisms and promising therapeutic strategies to reduce tumor recurrence through alleviating inflammation induced by hepatic IRI.
炎症对于肿瘤发生和转移的发展至关重要。肝缺血/再灌注损伤（IRI）是肝切除和肝移植中尚未解决的问题，它常常在肝脏中建立和重塑炎症微环境。越来越多的实验和临床证据揭示了肝IRI 及其相关炎症在促进肝细胞癌（HCC）复发中的作用。同时，旨在减轻肝IRI 的方法，如机器灌注、调节肠-肝轴和靶向关键炎症成分，已被证明可预防 HCC 复发。本文综述了通过减轻肝 IRI 引起的炎症来降低肿瘤复发的潜在机制和有前途的治疗策略。
